期刊
TICKS AND TICK-BORNE DISEASES
卷 7, 期 4, 页码 549-564出版社
ELSEVIER GMBH
DOI: 10.1016/j.ttbdis.2016.02.001
关键词
Theileria parva; East Coast fever; Vaccines; Infection and treatment; Antigens
资金
- ILRI
- IFAD
- USA National Science Foundation [0965346]
- CGIAR Research Program on Livestock and Fish
- Norman Borlaug Commemorative Research Initiative [58-5348-2-117F]
- Department for International Development of the United Kingdom
- Bill and Melinda Gates Foundation [OPP1078791]
Tremendous progress has been made over the last ten years on East Coast fever (ECF) research. Publication of a reference genome sequence of Theileria parva, the causative agent of ECF, has led to a more thorough characterization of the genotypic and antigenic diversity of the pathogen. It also facilitated identification of antigens that are targets of bovine major histocompatibility complex class I restricted cytotoxic T-lymphocytes (CTLs), induced by a live parasite-based infection and treatment method (ITM) vaccine. This has led to improved knowledge of epitope-specific T-cell responses to ITM that most likely contribute to the phenomenon of strain-specific immunity. The Muguga cocktail ITM vaccine, which provides broad-spectrum immunity to ECF is now a registered product in three countries in eastern Africa. Effort is directed at improving and scaling up the production process to make this vaccine more widely available on a commercial basis in the region. Meanwhile, research to develop a subunit vaccine based on parasite neutralizing antibodies and CTLs has been revived through convening of a research consortium to develop proof-of-concept for a next generation vaccine. Many new scientific and technical advances are facilitating this objective. Hence, the next decade promises even more progress toward an improved control of ECF. (C) 2016 The Authors. Published by Elsevier GmbH.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据